Fidelity Investments’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2
| Closed | – | – | 5773 |
|
|
2024
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 5871 |
|
|
2024
Q3 | $4 | Buy |
+2
| New | +$7 | ﹤0.01% | 5462 |
|
|
2024
Q2 | – | Sell |
-71
| Closed | -$380 | – | 5685 |
|
|
2024
Q1 | $380 | Buy |
+71
| New | +$491 | ﹤0.01% | 4866 |
|
|
2023
Q4 | – | Sell |
-346
| Closed | -$1.37K | – | 5693 |
|
|
2023
Q3 | $1.37K | Buy |
346
+249
| +257% | +$932 | ﹤0.01% | 4606 |
|
|
2023
Q2 | $306 | Buy |
+97
| New | +$312 | ﹤0.01% | 4869 |
|
|
2023
Q1 | – | Sell |
-12
| Closed | -$43 | – | 5579 |
|
|
2022
Q4 | $43 | Sell |
12
-252,017
| -100% | -$1.09M | ﹤0.01% | 4972 |
|
|
2022
Q3 | $1.62M | Sell |
252,029
-10,279
| -4% | -$83.5K | ﹤0.01% | 2481 |
|
|
2022
Q2 | $2.52M | Sell |
262,308
-290,330
| -53% | -$2.72M | ﹤0.01% | 2437 |
|
|
2022
Q1 | $6.58M | Sell |
552,638
-353,492
| -39% | -$6.32M | ﹤0.01% | 2286 |
|
|
2021
Q4 | $29.5M | Buy |
906,130
+245
| +0% | +$9.92K | ﹤0.01% | 1639 |
|
|
2021
Q3 | $40.5M | Buy |
905,885
+1,088
| +0.1% | +$53.1K | ﹤0.01% | 1504 |
|
|
2021
Q2 | $49.3M | Buy |
904,797
+3,286
| +0.4% | +$194K | ﹤0.01% | 1437 |
|
|
2021
Q1 | $67.4M | Buy |
901,511
+237,427
| +36% | +$24.7M | 0.01% | 1252 |
|
|
2020
Q4 | $72.1M | Buy |
664,084
+729
| +0.1% | +$66.5K | 0.01% | 1173 |
|
|
2020
Q3 | $58.6M | Buy |
663,355
+1,035
| +0.2% | +$118K | 0.01% | 1132 |
|
|
2020
Q2 | $70.6M | Buy |
662,320
+34,422
| +5% | +$3.09M | 0.01% | 1028 |
|
|
2020
Q1 | $37.2M | Buy |
627,898
+14,357
| +2% | +$974K | 0.01% | 1141 |
|
|
2019
Q4 | $42.4M | Buy |
613,541
+45
| +0% | +$2.73K | ﹤0.01% | 1280 |
|
|
2019
Q3 | $63.7M | Buy |
613,496
+52
| +0% | +$4.91K | 0.01% | 1068 |
|
|
2019
Q2 | $56.8M | Buy |
613,444
+108,628
| +22% | +$7.56M | 0.01% | 1161 |
|
|
2019
Q1 | $46.1M | Hold |
504,816
| – | – | 0.01% | 1252 |
|
|
2018
Q4 | $28.1M | Hold |
504,816
| – | – | ﹤0.01% | 1419 |
|
|
2018
Q3 | $60.1M | Buy |
504,816
+16,141
| +3% | +$1.87M | 0.01% | 1170 |
|
|
2018
Q2 | $49.9M | Buy |
488,675
+5,766
| +1% | +$714K | 0.01% | 1272 |
|
|
2018
Q1 | $62.7M | Buy |
482,909
+88,462
| +22% | +$9.67M | 0.01% | 1194 |
|
|
2017
Q4 | $38.4M | Buy |
394,447
+544
| +0.1% | +$73.1K | ﹤0.01% | 1421 |
|
|
2017
Q3 | $58M | Buy |
393,903
+1,203
| +0.3% | +$226K | 0.01% | 1238 |
|
|
2017
Q2 | $63.2M | Buy |
392,700
+41,806
| +12% | +$6.57M | 0.01% | 1193 |
|
|
2017
Q1 | $55.9M | Buy |
350,894
+187
| +0.1% | +$22.8K | 0.01% | 1254 |
|
|
2016
Q4 | $42.6M | Buy |
350,707
+91
| +0% | +$12.8K | 0.01% | 1376 |
|
|
2016
Q3 | $48.6M | Buy |
350,616
+47,887
| +16% | +$6.08M | 0.01% | 1307 |
|
|
2016
Q2 | $37.8M | Buy |
+302,729
| New | +$54.9M | 0.01% | 1395 |
|
Other funds holding SYRS
BBA
1CM
XT
Fidelity Investments's SYRS Position: Q1 2025 in Review
Fidelity Investments sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 2 shares.
Fidelity Investments first reported a position in SYRS in Q2 2016 and held it in 32 quarters. The position peaked at $72.1M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Fidelity Investments reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Fidelity Investments sold 2 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025.
- Fidelity Investments first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 32 quarters.
- Fidelity Investments's Syros Pharmaceuticals, Inc. Common Stock position peaked at $72.1M in Q4 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.